Synopsys saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an increase from 68 to 76.
Can You Really Time The Stock Market?
IBD's unique rating measures price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating of above 80 in the early stages of their moves. See if Synopsys can continue to rebound and clear that threshold.
While Synopsys is not near an ideal buying range right now, see if it goes on to form and break out of a proper consolidation.
Synopsys saw both earnings and sales growth rise last quarter. Earnings-per-share increased from -10% to 22%. Revenue rose from -4% to 10%.
The company earns the No. 2 rank among its peers in the Computer Software-Design industry group. Cadence Design Systems is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
